NCT00304005View on ClinicalTrials.gov

VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

October 31, 2005

Study Completion Date

August 31, 2008

Conditions
LeukemiaLymphoma
Interventions
DRUG

laromustine

Trial Locations (1)

77030-4009

M.D. Anderson Cancer Center at University of Texas, Houston

Sponsors
All Listed Sponsors
lead

Vion Pharmaceuticals

INDUSTRY

NCT00304005 - VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders | Biotech Hunter | Biotech Hunter